Spry review

Spry does several useful things. It names three co-founders, shows its prices on the homepage instead of behind a sign-up wall, displays a LegitScript seal with a public verification link, requires no contracts, and states that a licensed nurse practitioner reviews intake within 24 hours. Its longevity shelf names three molecules: BPC-157, NAD⁺ and sermorelin. One thing outweighs all of it for a reader trying to work out what is true: everything on sale is compounded, and no page says so or says that the products are not FDA-approved. The only regulatory phrase on the homepage is the alt text on its photo of vials, which reads "FDA Approved".

Spry is a weight-loss and anti-aging telehealth service selling five products: compounded semaglutide and compounded tirzepatide under Weight Loss, and BPC-157, NAD⁺ and sermorelin under Anti-Aging. It names three co-founders — Gabriel Mullins, Sara Yoder and Tyler Bowman — and states that its team has more than twenty years of experience, without publishing clinical credentials for any of them. It does not accept insurance but states it can supply documentation to help you submit a claim yourself. It displays a LegitScript seal with a link to the public checker.

Asynchronous intake reviewed by a licensed nurse practitioner, stated in its own FAQ as happening within 24 hours, with no contracts and no commitment requirements. Naming three co-founders publicly is above the norm for this segment and worth crediting; not publishing any clinical credential for them is a straightforward miss, because the founders of a telehealth company are not the same thing as its prescribers, and the site does not name a medical director either. The bigger issue is disclosure. The site sells compounded semaglutide, tirzepatide and peptides, none of which are FDA-approved finished drug products, yet no page says they are compounded, and the standard compounded-medication disclaimer is absent. The alt text on its homepage vial photo reads "FDA Approved", which points the wrong way. That is not a small formatting quibble on a page selling injectables. Also undisclosed: the states it serves, its pharmacy partner, whether that pharmacy is 503A or 503B, its corporate legal entity, its governing law and any refund terms beyond "no contracts".

Shown on the homepage, which is genuinely better than a sign-up wall. The homepage tiles read "Starting at $249.00" for BPC-157 and sermorelin and "Starting at $299.00" for NAD⁺, and the longevity page states the period: BPC-157 and sermorelin are $249 a month and NAD⁺ is $299 a month. Compounded semaglutide starts at $199 and tirzepatide at $299. There is no membership fee stacked underneath, and no contract, both of which are stated plainly. One thing to establish before ordering: what the monthly price becomes when a provider raises your dose, since no dose ladder is published for any product. Ask in writing.

Compounded; not FDA-approved — a statement the site itself does not make, which is the core problem with this listing. Prescription required only if a licensed provider finds it appropriate. No pharmacy partner is named, no 503A or 503B designation is given, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, its three anti-aging products sit on three different tiers and are priced as though they were equivalent. Sermorelin is a GHRH analog that stimulates your own pituitary — a real, well-characterized mechanism whose long-term human outcome data stays thin past short-term IGF-1 movement. Injected NAD⁺ has no controlled human outcome trials at all; the NAD⁺ forms with human trial data are the oral precursors NR and NMN, and what those trials show is a raised blood NAD⁺ level rather than a clinical outcome. BPC-157 is the weakest of the three: it has no controlled human outcome trials, its reputation rests on rodent work, and its presence on a menu is a reasonable signal of how a service selects what to sell. Individual results vary.